MedTrace Logo

Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma

NCT04042805 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-03-02

No results posted yet for this study

Summary

This ia a single-arm, single-center, not-randomized, open-label phase II study. The purpose of this study is to evaluate the efficacy and safety of Sintilimab (PD-1 antibody) combined with Lenvatinib(TKI) for the treatment of local advanced hepatocellular carcinoma.

Conditions

Interventions

BIOLOGICAL

Sintilimab

200mg intravenously every 3 weeks

DRUG

Lenvatinib

12 mg (or 8 mg) once daily (QD) oral dosing.

Sponsors & Collaborators

  • Baocai Xing

    lead OTHER

Principal Investigators

  • Baocai Xing, Doctor · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2022-08-30
Completion
2024-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04042805 on ClinicalTrials.gov